Scientists have discovered a possible link between the development of colon cancer and a 'silent' condition that affects more ...

GSK will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British pharma giant said Wednesday that it will pay the ...

GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion. The deal includes an upfront payment of $1.2 billion and milestone payments.

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

Poor diet, sedentary lifestyle, and metabolic issues like obesity and insulin resistance often result in fatty liver disease ...

Alcohol use is also linked to cognitive decline, and a recent study published in the journal Neurology found that consuming a ...

Q1 2025 Management View CEO Vipin Garg highlighted the imminent readout of the IMPACT Phase 2b NASH trial, stating "we are confident of achieving the trial’s key efficacy and safety objectives" and ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Severe alcohol-associated hepatitis (sAH) remains a highly lethal condition with limited therapeutic options. Characterized by rapid liver decompensation, sAH is often accompanied by acute kidney ...

Discover a study that has proposed a predictive model for cirrhosis and hepatocellular carcinoma in individuals with ...

The weight loss drug Wegovy treated a serious form of liver disease in about two-thirds of patients in a major clinical trial. The Fox Medical Team's Dr. Mike Cirigliano joined Good Day to take a look ...

(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...